Xilio Therapeutics, Inc. Proceeds from Issuance of Private Placement
Xilio Therapeutics, Inc. (XLO) reported Proceeds from Issuance of Private Placement of $4.31 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2024-05-14
- Xilio Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2024-03-31 was $4.31M.
| Period end | Proceeds from Issuance of Private Placement 3 month |
|---|---|
| 2024-03-31 | $4.31M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |